Lab support for tumor and biomarker testing in advanced endometrial cancer
Pathology Core
['FUNDING_P01'] · DANA-FARBER CANCER INST · NIH-11323907
This program develops and runs tissue and lab tests to find DNA damage and immune signals in women with advanced endometrial cancer.
Quick facts
| Phase | ['FUNDING_P01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DANA-FARBER CANCER INST (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-11323907 on ClinicalTrials.gov |
What this research studies
From a patient's view, a pathology core team at Dana-Farber will handle tumor samples and make sure lab tests are done the same way every time. They will check human tumor tissue as well as lab-grown tumor models and mouse models to confirm those models match patients' tumors. The team will measure markers of DNA damage and replication stress (like g-H2AX, pKAP1, and pRPA) and link those results to drug approaches such as WEE1 or ATR/PI3K inhibitors and ways to boost immune responses. Their work helps study how tumors respond to these treatments and supports the larger projects that may lead to new therapy options.
Who could benefit from this research
Good fit: Women with advanced endometrial cancer—especially uterine serous or TP53‑mutant tumors—are the primary candidates for the related projects.
Not a fit: People without endometrial cancer, or those with tumors that lack DNA damage or replication‑stress features, are unlikely to benefit from these specific biomarker-driven approaches.
Why it matters
Potential benefit: If successful, this work could help match patients to treatments that exploit tumor DNA repair problems and potentially improve responses to therapy.
How similar studies have performed: Early clinical studies of DNA damage–targeting drugs and biomarker-guided approaches have shown promise, but the specific drug combinations and immune-activating strategies here remain experimental.
Where this research is happening
BOSTON, UNITED STATES
- DANA-FARBER CANCER INST — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SHAPIRO, GEOFFREY I. — DANA-FARBER CANCER INST
- Study coordinator: SHAPIRO, GEOFFREY I.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.